4582 SymBio Pharmaceuticals Limitedシンバイオ製薬TSE Growth / Pharmaceuticals
0 posts
SymBio Pharmaceuticals Limited stock plunged on Nov 20: what happened
It closed at ¥69.0 on Nov 20 (−¥9.0, −11.54%), ranking #39 among the top losers of all stocks on the Tokyo Stock Exchange.
No disclosures were found for this stock around that day. Share what you know in the posts below.
Changes are calculated from the closing prices this site collects daily; limit-up/down is an estimate based on the daily price limit. Please make your own investment decisions.
SymBio Pharmaceuticals Limited (4582) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
SymBio Pharmaceuticals Limited (4582) Stock Price History
SymBio Pharmaceuticals Limited closed at ¥69.0 on Nov 20, 2026, +40.8% over 1 month, −33.0% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥140,816 today (+40.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved +40.8%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥69.0 | −9 | −11.54% |
| Nov 19 (Thu) | ¥78.0 | +7 | +9.86% |
| Nov 18 (Wed) | ¥71.0 | −4 | −5.33% |
| Nov 17 (Tue) | ¥75.0 | +11 | +17.19% |
| Nov 16 (Mon) | ¥64.0 | +5 | +8.47% |
| Nov 13 (Fri) | ¥59.0 | +7 | +13.46% |
| Nov 12 (Thu) | ¥52.0 | −4 | −7.14% |
| Nov 10 (Tue) | ¥56.0 | −12 | −17.65% |
| Nov 6 (Fri) | ¥68.0 | −4 | −5.56% |
| Nov 5 (Thu) | ¥72.0 | +30 | +71.43% |
If you had invested ¥100,000 3 months ago, it would be worth ¥104,545 today (+4.5%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved +4.5%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥69.0 | −9 | −11.54% |
| Nov 19 (Thu) | ¥78.0 | +7 | +9.86% |
| Nov 18 (Wed) | ¥71.0 | −4 | −5.33% |
| Nov 17 (Tue) | ¥75.0 | +11 | +17.19% |
| Nov 16 (Mon) | ¥64.0 | +5 | +8.47% |
| Nov 13 (Fri) | ¥59.0 | +7 | +13.46% |
| Nov 12 (Thu) | ¥52.0 | −4 | −7.14% |
| Nov 10 (Tue) | ¥56.0 | −12 | −17.65% |
| Nov 6 (Fri) | ¥68.0 | −4 | −5.56% |
| Nov 5 (Thu) | ¥72.0 | +30 | +71.43% |
If you had invested ¥100,000 6 months ago, it would be worth ¥84,146 today (−15.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved −15.9%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥69.0 | +56.8% |
| Oct 2026 | ¥44.0 | −21.4% |
| Sep 2026 | ¥56.0 | −12.5% |
| Aug 2026 | ¥64.0 | −7.2% |
| Jul 2026 | ¥69.0 | +0.0% |
| Jun 2026 | ¥69.0 | −12.7% |
| May 2026 | ¥79.0 | −14.1% |
If you had invested ¥100,000 1 year ago, it would be worth ¥65,714 today (−34.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +16.1%, while this stock moved −34.3%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥69.0 | +56.8% |
| Oct 2026 | ¥44.0 | −21.4% |
| Sep 2026 | ¥56.0 | −12.5% |
| Aug 2026 | ¥64.0 | −7.2% |
| Jul 2026 | ¥69.0 | +0.0% |
| Jun 2026 | ¥69.0 | −12.7% |
| May 2026 | ¥79.0 | −14.1% |
| Apr 2026 | ¥92.0 | −17.9% |
| Mar 2026 | ¥112 | −30.9% |
| Feb 2026 | ¥162 | +88.4% |
| Jan 2026 | ¥86.0 | −4.4% |
| Dec 2025 | ¥90.0 | −15.9% |
| Nov 2025 | ¥107 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥26,136 today (−73.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved −73.9%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥69.0 | −23.3% |
| 2025 | ¥90.0 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥4,672 today (−95.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −95.3%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥69.0 | −23.3% |
| 2025 | ¥90.0 | ― |
If you had invested ¥100,000 in Nov 2011, it would be worth ¥6,873 today (−93.1%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +567.5%, while this stock moved −93.1%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥69.0 | −23.3% |
| 2025 | ¥90.0 | −54.8% |
| 2024 | ¥199 | −19.4% |
| 2023 | ¥247 | −61.6% |
| 2022 | ¥643 | −43.8% |
| 2021 | ¥1,145 | +202.1% |
| 2020 | ¥379 | −37.6% |
| 2019 | ¥607 | −20.1% |
| 2018 | ¥760 | −13.2% |
| 2017 | ¥876 | −10.2% |
| 2016 | ¥976 | +5.2% |
| 2015 | ¥928 | −35.0% |
| 2014 | ¥1,428 | −6.1% |
| 2013 | ¥1,520 | +26.7% |
| 2012 | ¥1,200 | −37.2% |
| 2011 | ¥1,912 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Nov 2011). Please check the latest prices before trading.
SymBio Pharmaceuticals Limited (4582) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of SymBio Pharmaceuticals Limited (4582)
Business overview
Together with one consolidated subsidiary established as an overseas strategic base and others, the company runs research and development, manufacturing and sales of pharmaceuticals and related operations as a single segment. It was founded in March 2005 by 「吉田文紀」, a former corporate vice president at the headquarters of biopharmaceutical leader Amgen who served as president of its Japanese arm for about 12 years. Its management philosophy is co-creation and coexistence, and its business purpose is to connect doctors, scientists, governments and capital providers around patients to meet unmet medical needs where no effective drugs or treatments exist. Rare disease fields in oncology, hematology and viral infections require high expertise and are difficult to develop, making them hard for large pharmaceutical companies to take on for profitability and other reasons, and the company works on developing new drugs in these fields.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| Market cap | ¥5.8 bn | No. 58 in the sector (largest first) |
|---|
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥201 | 2/24 |
|---|---|---|
| 52-week low | ¥42 | 11/4 |
| Current position | 17.0% | Where the low is 0% and the high is 100% (close on 11/20: ¥69) |
| Year to date | -23.3% | No. 47 of 77 in the sector (best first) |
| 1 year | -33.0% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 4 times | Latest: 11/19 (No. 14) |
|---|---|---|
| Top 50 losers | 4 times | Latest: 11/20 (No. 39) |
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/09 15:30第三者割当により発行された第70回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
- 11/06 15:30第三者割当により発行された第70回新株予約権(行使価額修正条項付)の 大量行使に関するお知らせ
- 11/02 15:30第三者割当により発行された第70回新株予約権及び第71回新株予約権(行使価額修正条項付)の 月間行使状況に関するお知らせ
- 10/29 15:302026年12月期第3四半期決算短信〔日本基準〕(連結)
- 10/29 11:25資金の借入に関するお知らせ
- 10/06 08:44ブリンシドホビル(BCV)の英国における条件付き早期製造販売承認(CMA)取得に向けた協議開始
- 10/01 16:57第三者割当により発行された第70回新株予約権及び第71回新株予約権(行使価額修正条項付)の 月間行使状況に関するお知らせ
- 09/24 08:33多発性硬化症の独占的グローバルライセンスを取得 米国保健福祉省との間で、BCVに関する開発のライセンス契約締結
Filings from the past 12 months (8).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the SymBio Pharmaceuticals Limited board
More Japanese stocks in English
- Chiome Bioscience Inc.4583
- Kidswell Bio Corporation4584
- Medrx Co.,Ltd.4586
- PeptiDream Inc.4587
- Oncolys BioPharma Inc.4588
- PLAN DO Co.,Ltd.458A
- RIBOMIC Inc.4591
- SanBio Company Limited4592
- HEALIOS K.K.4593
- BrightPath Biotherapeutics Co.,Ltd.4594
- MIZUHO MEDY CO.,LTD.4595
- Kubota Pharmaceutical Holdings Co.,Ltd.4596